Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Rashmi Kumari

RARE PHOTOS: Earnings preview what to expect from regeneron pharmaceuticals report | Rare Historical Photos

Based in Tarrytown, New York, Regeneron Pharmaceuticals, Inc. (REGN) is a biotechnology company focused on discovering, developing, and commercializing innovative medicines. It is known for its robust pipeline and successful products such as EYLEA and Dupixent. With a market cap of $119.62 billion, Regeneron is a recognized leader in the biotechnology industry, dedicated to advancing science and delivering transformative therapies. The company is set to announce its fiscal Q2 earnings results before the market opens on Thursday, Aug. 1.

Ahead of the event, analysts expect REGN to report a profit of $8.89 per share, up 1.1% from $8.79 per share in the year-ago quarter. In the last four quarters, the company has surpassed Wall Street’s bottom-line estimates in three and missed on another occasion.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.